Gliomas Infiltrating the Corpus Callosum: A Systematic Review of the Literature.

butterfly glioma corpus callosum glioblastoma neuro-oncology survival

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
19 May 2022
Historique:
received: 14 04 2022
revised: 01 05 2022
accepted: 18 05 2022
entrez: 28 5 2022
pubmed: 29 5 2022
medline: 29 5 2022
Statut: epublish

Résumé

Background: Gliomas infiltrating the corpus callosum (G-I-CC) majorly impact patient quality-of-life, but maximally safe tumor resection is challenging. We systematically reviewed the literature on G-I-CC. Methods: PubMed, EMBASE, Scopus, Web of Science, and Cochrane were searched following the PRISMA guidelines to include studies of patients with G-I-CC. Clinicopathological features, treatments, and outcomes were analyzed. Results: We included 52 studies comprising 683 patients. Most patients experienced headache (33%), cognitive decline (18.7%), and seizures (17.7%). Tumors mostly infiltrated the corpus callosum genu (44.2%) with bilateral extension (85.4%) into frontal (68.3%) or parietal (8.9%) lobes. Most G-I-CC were glioblastomas (84.5%) with IDH-wildtype (84.9%) and unmethylated MGMT promoter (53.5%). Resection (76.7%) was preferred over biopsy (23.3%), mostly gross-total (33.8%) and subtotal (32.5%). The tumor-infiltrated corpus callosum was resected in 57.8% of cases. Radiation was delivered in 65.8% of patients and temozolomide in 68.3%. Median follow-up was 12 months (range, 0.1−116). In total, 142 patients (31.8%) experienced post-surgical complications, including transient supplementary motor area syndrome (5.1%) and persistent motor deficits (4.3%) or abulia (2.5%). Post-treatment symptom improvement was reported in 42.9% of patients. No differences in rates of complications (p = 0.231) and symptom improvement (p = 0.375) were found in cases with resected versus preserved corpus callosum. Recurrences occurred in 40.9% of cases, with median progression-free survival of 9 months (0.1−72). Median overall survival was 10.7 months (range, 0.1−116), significantly longer in low-grade tumors (p = 0.013) and after resection (p < 0.001), especially gross-total (p = 0.041) in patients with high-grade tumors. Conclusions: G-I-CC show clinicopathological patterns comparable to other more frequent gliomas. Maximally safe resection significantly improves survival with low rates of persistent complications.

Identifiants

pubmed: 35626112
pii: cancers14102507
doi: 10.3390/cancers14102507
pmc: PMC9139932
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States

Références

Sci Rep. 2020 Oct 6;10(1):16630
pubmed: 33024247
Neuro Oncol. 2005 Jan;7(1):97-100
pubmed: 15701287
Nat Rev Cancer. 2020 Jan;20(1):57-70
pubmed: 31806884
Eur J Radiol. 2019 Mar;112:106-111
pubmed: 30777198
World Neurosurg. 2021 Oct;154:e734-e742
pubmed: 34358688
J Korean Neurosurg Soc. 2014 Sep;56(3):261-4
pubmed: 25368772
J Neurosurg. 2004 Mar;100(3):431-7
pubmed: 15035278
Acta Neurochir (Wien). 2022 Mar;164(3):689-702
pubmed: 34636967
Neurosurgery. 1982 Jul;11(1 Pt 1):68-72
pubmed: 7110572
J Neurooncol. 2022 Feb;156(3):635-644
pubmed: 35032284
Radiol Case Rep. 2021 Jul 15;16(9):2663-2667
pubmed: 34345327
BMJ Case Rep. 2021 Dec 30;14(12):
pubmed: 34969804
Nat Rev Clin Oncol. 2018 Feb;15(2):112-125
pubmed: 29158591
Acta Neurochir (Wien). 2021 Jul;163(7):1883-1894
pubmed: 33871698
J Neurol Neurosurg Psychiatry. 2005 Jun;76(6):845-51
pubmed: 15897509
J Neurooncol. 2019 Jan;141(1):167-182
pubmed: 30446902
Radiol Case Rep. 2020 Dec 03;16(2):319-326
pubmed: 33304444
J Neurooncol. 2012 Sep;109(3):555-63
pubmed: 22806339
Neurosurgery. 1992 Oct;31(4):741-5
pubmed: 1407461
J Neurooncol. 2015 Nov;125(2):393-400
pubmed: 26376654
J Clin Neurosci. 2009 Aug;16(8):1086-8
pubmed: 19409792
World Neurosurg. 2020 Dec;144:e156-e163
pubmed: 32795682
J Neurooncol. 2019 Sep;144(3):573-582
pubmed: 31410731
BMJ. 2021 Mar 29;372:n71
pubmed: 33782057
Front Oncol. 2022 Feb 01;12:818446
pubmed: 35178348
Neuroimage. 2021 Feb 15;227:117642
pubmed: 33338619
Clin Neurol Neurosurg. 2011 Jun;113(5):407-10
pubmed: 21208740
J Neurooncol. 2017 Apr;132(2):341-349
pubmed: 28074322
J Neurooncol. 1998 May;38(1):83-9
pubmed: 9540061
J Clin Neurosci. 1999 Jan;6(1):68-70
pubmed: 18639131
Surg Neurol Int. 2020 Nov 06;11:372
pubmed: 33408906
J Neurooncol. 2021 Jun;153(2):273-281
pubmed: 33907967
BMJ Case Rep. 2016 Dec 15;2016:
pubmed: 27979842
Front Neurosci. 2021 Jul 30;15:701426
pubmed: 34393714
World Neurosurg. 2019 Jul;127:213-215
pubmed: 30974270
Am J Ophthalmol. 1970 Apr;69(4):594-8
pubmed: 5309572
Acta Neurochir (Wien). 2021 Apr;163(4):937-945
pubmed: 33095353
Singapore Med J. 2017 Mar;58(3):121-125
pubmed: 28361164
Neurosurg Focus. 2018 Jun;44(6):E4
pubmed: 29852771
World Neurosurg. 2018 Feb;110:e612-e620
pubmed: 29162526
J Neurooncol. 2005 Jul;73(3):239-40
pubmed: 15980974
World Neurosurg. 2020 Dec;144:162-169
pubmed: 32861903
Cancer Genet Cytogenet. 2007 Sep;177(2):125-30
pubmed: 17854667
Neurol Med Chir (Tokyo). 1990 Aug;30(8):604-9
pubmed: 1703639
J Clin Oncol. 2011 Oct 20;29(30):3999-4006
pubmed: 21931021
J Neurosurg. 2018 May;128(5):1438-1447
pubmed: 28686110
AMA Arch Neurol Psychiatry. 1958 Sep;80(3):298-303
pubmed: 13570745
J Neurooncol. 2014 Dec;120(3):625-34
pubmed: 25193022
N Engl J Med. 1949 Dec 22;241(25):1020-4, illust
pubmed: 15408539
Br J Neurosurg. 2004 Aug;18(4):391-5
pubmed: 15702843
J Neurooncol. 2015 Sep;124(2):207-14
pubmed: 26033546
Brain Tumor Pathol. 2011 Oct;28(4):305-9
pubmed: 21833577
Int Med Case Rep J. 2019 Jul 05;12:205-211
pubmed: 31308765
Acta Neurochir (Wien). 2020 Jul;162(7):1691-1699
pubmed: 32440925
J Clin Neurosci. 2019 Feb;60:153-155
pubmed: 30528355
Anticancer Res. 2022 Mar;42(3):1189-1198
pubmed: 35220208
Nat Cell Biol. 2020 Jan;22(1):97-107
pubmed: 31907411
JAMA. 2015 Apr 28;313(16):1657-65
pubmed: 25919529
World Neurosurg. 2019 Nov;131:174-176
pubmed: 31415896
J Neurosurg Sci. 2020 Jun;64(3):302-304
pubmed: 29671292
N Engl J Med. 2005 Aug 25;353(8):811-22
pubmed: 16120861
Acta Neurochir (Wien). 2009 Feb;151(2):137-40
pubmed: 19194655
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
J Neurosurg. 2021 Dec 14;:1-10
pubmed: 34905728
Cureus. 2020 Feb 7;12(2):e6914
pubmed: 32190469
Int J Radiat Oncol Biol Phys. 1997 Apr 1;38(1):27-30
pubmed: 9212000
Sci Rep. 2021 Jul 6;11(1):13934
pubmed: 34230597
Neurol Med Chir (Tokyo). 1998 May;38(5):283-6
pubmed: 9640964
J Neurooncol. 2021 Dec;155(3):215-224
pubmed: 34797525
NMC Case Rep J. 2019 Dec 18;7(1):39-41
pubmed: 31938681
J Neurosurg. 2017 Jun;126(6):1795-1811
pubmed: 27636183
J Cancer Res Ther. 2009 Jan-Mar;5(1):43-5
pubmed: 19293489
J Neurooncol. 2021 Dec;155(3):383-384
pubmed: 34800209
JAMA Oncol. 2016 Nov 01;2(11):1460-1469
pubmed: 27310651
Neuro Oncol. 2021 Oct 5;23(12 Suppl 2):iii1-iii105
pubmed: 34608945

Auteurs

Paolo Palmisciano (P)

Department of Neurosurgery, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA.

Gianluca Ferini (G)

Department of Radiation Oncology, REM Radioterapia srl, 95029 Viagrande, Italy.

Gina Watanabe (G)

John A. Burns School of Medicine, University of Hawai'i, Honolulu, HI 96813, USA.

Christian Ogasawara (C)

John A. Burns School of Medicine, University of Hawai'i, Honolulu, HI 96813, USA.

Emal Lesha (E)

Department of Neurosurgery, University of Tennessee Health Science Center, Memphis, TN 38163, USA.

Othman Bin-Alamer (O)

Department of Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA.

Giuseppe E Umana (GE)

Department of Neurosurgery, Trauma Center, Gamma Knife Center, Cannizzaro Hospital, 95126 Catania, Italy.

Kenny Yu (K)

Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Aaron A Cohen-Gadol (AA)

Department of Neurological Surgery, Indiana University School of Medicine, Indianapolis, IN 46202, USA.

Tarek Y El Ahmadieh (TY)

Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Ali S Haider (AS)

Department of Neurosurgery, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.

Classifications MeSH